Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
PTC Therapeutics’ Translarna for nmDMD is Conditionally Approved in European Union
Recent Posts
- ALS caregivers across Canada can now access free professional counseling
- When an ALS caregiver takes a much-needed break from the daily routine
- Advocates push for swift passage of ACT for ALS reauthorization bill
- How to not get angry when trying to force a square peg into a round hole
- Shionogi completes acquisition of rights to ALS drug Radicava